Search results for "peptidase"

showing 10 items of 567 documents

Association of obesity with proteasomal gene polymorphisms in children.

2013

The aim of this study was to ascertain possible associations between childhood obesity, its anthropometric and clinical parameters, and three loci of proteasomal genes rs2277460 (PSMA6c.-110C>A), rs1048990 (PSMA6c.-8C>G), and rs2348071 (PSMA3c. 543+138G>A) implicated in obesity-related diseases. Obese subjects included 94 otherwise healthy children in Latvia. Loci were genotyped and then analyzed using polymerase chain reactions, with results compared to those of 191 nonobese controls.PSMA3SNP frequency differences between obese children and controls, while not reaching significance, suggested a trend. These differences, however, proved highly significant (P<0.002) in the subset…

Blood GlucoseMalelcsh:Internal medicinePediatric ObesityProteasome Endopeptidase ComplexArticle SubjectAdolescentGenotypeEndocrinology Diabetes and MetabolismPSMA6Blood PressurePSMA3Polymorphism Single NucleotideChildhood obesityBody Mass IndexmedicineHumansGenetic Predisposition to Diseaselcsh:RC31-1245ChildGeneGeneticsAnalysis of Variancebusiness.industryCholesterol LDLAnthropometrymedicine.diseaseObesityCase-Control StudiesChild PreschoolFemalebusinessResearch ArticleJournal of obesity
researchProduct

Predictors of early discontinuation of dapagliflozin versus other glucose-lowering medications: a retrospective multicenter real-world study

2020

Background and aims: In routine clinical practice, early discontinuation of newly initiated glucose-lowering medications (GLM) is relatively common. We herein evaluated if the clinical characteristics associated with early discontinuation of dapagliflozin were different from those associated with early discontinuation of other GLM. Methods: The DARWIN-T2D was a multicenter retrospective study conducted at diabetes specialist outpatient clinics in Italy. We included 2484 patients who were initiated on dapagliflozin in 2015–2016 and 14,801 patients who were initiated on other GLM (DPP-4 inhibitors, GLP-1 receptor agonists, or gliclazide) in the same period. After excluding patients who had no…

Blood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolism030209 endocrinology & metabolismType 2 diabetes03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyGlucosidesDiabetes mellitusInternal medicineAdherence; Observational; Pharmacotherapy; Real-world; Type 2 diabetes; Aged; Benzhydryl Compounds; Blood Glucose; Diabetes Mellitus Type 2; Dipeptidyl-Peptidase IV Inhibitors; Female; Glucosides; Humans; Hypoglycemic Agents; Male; Middle Aged; Retrospective Studies; Withholding TreatmentDiabetes MellitusmedicineHumansHypoglycemic AgentsOutpatient clinicBenzhydryl CompoundsDapagliflozinObservationalAgedRetrospective StudiesDipeptidyl-Peptidase IV InhibitorsAdherence; Observational; Pharmacotherapy; Real-world; Type 2 diabetesbusiness.industryType 2 diabetesRetrospective cohort studyMiddle Agedmedicine.diseasePharmacotherapyMetforminDiscontinuationDiabetes Mellitus Type 2Real-worldWithholding TreatmentchemistryTolerabilityAdherence030220 oncology & carcinogenesisFemalebusinessType 2medicine.drugJournal of Endocrinological Investigation
researchProduct

Effect of vildagliptin compared to glimepiride on postprandial proinsulin processing in the β cell of patients with type 2 diabetes mellitus

2012

This study compared the effect of Glimepiride versus Vildagliptin on β-cell function and the release of intact proinsulin (PI) in patients with type 2 diabetes mellitus. Patients on metformin monotherapy were randomized to add on treatment with Vildagliptin or Glimepiride. A standardized test meal was given at baseline, after 12 and 24 weeks of treatment. Insulin, PI and blood glucose values were measured in the fasting state and postprandial for 300 min. Fasting PI levels significantly decreased in the Vildagliptin group. The area under the curve for the postprandial release of PI decreased during Vildagliptin and increased during Glimepiride treatment. The proinsulin to insulin ratio decl…

Blood GlucoseMalemedicine.medical_specialtyPyrrolidinesendocrine system diseasesEndocrinology Diabetes and Metabolismmedicine.medical_treatmentAdamantaneEndocrinologyDiabetes mellitusInternal medicineNitrilesInternal MedicinemedicineHumansHypoglycemic AgentsVildagliptinProinsulinVildagliptinDipeptidyl-Peptidase IV Inhibitorsbusiness.industryInsulinnutritional and metabolic diseasesType 2 Diabetes MellitusPostprandial Periodmedicine.diseaseMetforminMetforminGlimepirideSulfonylurea CompoundsTreatment OutcomePostprandialEndocrinologyDiabetes Mellitus Type 2Area Under CurveDrug Therapy CombinationFemalebusinessProinsulinmedicine.drugDiabetes, Obesity and Metabolism
researchProduct

Native, Intact Glucagon-Like Peptide 1 Is a Natural Suppressor of Thrombus Growth Under Physiological Flow Conditions

2020

Objective: In patients with diabetes mellitus, increased platelet reactivity predicts cardiac events. Limited evidence suggests that DPP-4 (dipeptidyl peptidase 4) influences platelets via GLP-1 (glucagon-like peptide 1)-dependent effects. Because DPP-4 inhibitors are frequently used in diabetes mellitus to improve the GLP-1-regulated glucose metabolism, we characterized the role of DPP-4 inhibition and of native intact versus DPP-4-cleaved GLP-1 on flow-dependent thrombus formation in mouse and human blood. Approach and Results: An ex vivo whole blood microfluidics model was applied to approach in vivo thrombosis and study collagen-dependent platelet adhesion, activation, and thrombus for…

Blood Platelets0301 basic medicineendocrine systemmedicine.medical_specialtyPlatelet AggregationPLATELET ACTIVATIONLinagliptin030204 cardiovascular system & hematologyDPP4Glucagon-Like Peptide-1 Receptorlaw.invention03 medical and health sciences0302 clinical medicinedipeptidyl peptidase 4Fibrinolytic AgentslawInternal medicineDiabetes mellitusmedicineAnimalsHumansPlateletIn patientThrombusglucose610 Medicine & healthDipeptidyl peptidase-4Mice KnockoutDipeptidyl-Peptidase IV InhibitorsChemistryPharmacology. TherapySitagliptin Phosphatedigestive oral and skin physiologyThrombosismedicine.diseaseGlucagon-like peptide-1Peptide Fragmentsglucagon-like peptide 1Mice Inbred C57BLMICE030104 developmental biologyEndocrinologyPhysiological flowdiabetes mellitusplateletsSuppressorHuman medicineCardiology and Cardiovascular MedicineSignal Transduction
researchProduct

Demonstration of High-Affinity Binding Sites for C3a Anaphylatoxin on Guinea-Pig Platelets

1978

3H-serotonin release from guinea-pig platelets was demonstrated to be the consequence of C3a binding to these cells. A Scatchard analysis of dose-response data of the 125I-C3a binding pattern to guinea-pig platelets pointed to the existence of binding sites with high and low affinity for the C3a molecule (HA and LA receptors). HA receptors are specific for C3a with intact C-terminal arginine. whereas C3adesarg only interacts with LA receptors. The release of serotonin may be induced by a combined reaction of C3a with HA receptors and LA receptors on the platelet membrane.

Blood PlateletsAnaphylatoxinsSerotoninBinding SitesArginineChemistryGuinea PigsImmunologyTemperaturechemical and pharmacologic phenomenaCarboxypeptidasesComplement C3General MedicineGuinea pigBiochemistryAnimalsProtease-activated receptorPlateletAnaphylatoxinSerotoninBinding sitePeptidesReceptorScandinavian Journal of Immunology
researchProduct

Meprin β: A novel regulator of blood–brain barrier integrity

2020

The metalloprotease meprin β (Mep1b) is capable of cleaving cell-adhesion molecules in different tissues (e.g. skin, kidney and intestine) and is dysregulated in several diseases associated with barrier breakdown (Alzheimer´s disease, kidney disruption, inflammatory bowel disease). In this study, we demonstrate that Mep1b is a novel regulator of tight junction (TJ) composition and blood–brain barrier (BBB) integrity in brain endothelium. In Mep1b-transfected mouse brain endothelial cells (bEnd.3), we observed a reduction of the TJ protein claudin-5, decreased transendothelial electrical resistance (TEER) and an elevated permeability to paracellular diffusion marker [14C]-inulin. Analysis o…

Blood–brain barrierOccludinMice03 medical and health sciences0302 clinical medicineCerebrospinal fluidIn vivomedicineAnimalsHumans030304 developmental biology0303 health sciencesMetalloproteinaseKidneyTight Junction ProteinsTight junctionChemistryBrainEndothelial CellsMetalloendopeptidasesOriginal ArticlesCell biologymedicine.anatomical_structureNeurologyBlood-Brain BarrierParacellular transportNeurology (clinical)Cardiology and Cardiovascular Medicine030217 neurology & neurosurgeryJournal of Cerebral Blood Flow & Metabolism
researchProduct

Development of peptidomimetic boronates as proteasome inhibitors.

2013

Abstract Proteasome inhibition has emerged over the past decade as an effective therapeutic approach for the treatment of hematologic malignancies. It is a multicatalytic complex, whose proteolytic activity relies in three types of subunits: chymotrypsin-like (β5), trypsin-like (β2) and caspase-like (β1). Most important for the development of effective antitumor agents is the inhibition of the β5 subunits. In this context, the dipeptide boronate bortezomib (Velcade ® ) represents the first proteasome inhibitor approved by the FDA and the lead compound in drug discovery. This paper describes the synthesis and biological evaluation of a series of conformationally constrained pseudopeptide bor…

Boron CompoundsModels MolecularProteasome Endopeptidase ComplexPeptidomimeticStructure-activity relationshipsPeptidomimetic boronates; Proteasome inhibitors; Docking studiesPharmacologyPeptidomimetic boronateDockingchemistry.chemical_compoundStructure-Activity RelationshipDrug DiscoverymedicineHumansProteasome inhibitorPharmacologyDipeptideDose-Response Relationship DrugMolecular StructureDrug discoveryBortezomibOrganic ChemistryGeneral MedicineBiochemistrychemistryProteasomeDocking (molecular)Proteasome inhibitorPeptidomimeticsLead compoundProteasome Inhibitorsmedicine.drugEuropean journal of medicinal chemistry
researchProduct

A new form of tumor and fetal collagen that binds laminin.

1993

Human breast and colon carcinoma tissues contain a form of collagen, not described before, composed of alpha 1 chains of similar size (approximately 100 kDa) but different charge. The three constitutive chains, separated by two-dimensional electrophoresis, are a unique acidic component, undetectable in other collagen types, with an apparent isoelectric point of 4-5, and two more basic components displaying the same electrophoretic behavior as alpha 1(III) and alpha 1(I), respectively. The acidic chain is structurally distinct from alpha 1(I) and displays a cyanogen bromide-derived fragment of similar size to CB5(III). This collagen in its native state is resistant to trypsin and metalloprot…

Breast NeoplasmsBiologyBiochemistryUmbilical Cordchemistry.chemical_compoundFetusLamininmedicineElectrochemistryAnimalsHumansTrypsinCyanogen BromideIsoelectric PointPolyacrylamide gel electrophoresisSkinchemistry.chemical_classificationMetalloproteinaseMetalloendopeptidasesTrypsinMolecular biologyPeptide FragmentsIntestinesMicroscopy ElectronIsoelectric pointchemistryImmunologyColonic Neoplasmsbiology.proteinCyanogen bromideCattleElectrophoresis Polyacrylamide GelCollagenLamininProtein AGlycoproteinmedicine.drugBiochemistry
researchProduct

Selective inhibition of binding of Bacillus thuringiensis Cry1Ab toxin to cadherin-like and aminopeptidase proteins in brush-border membranes and dis…

2007

Binding analyses with denatured epithelial membrane proteins from Bt (Bacillus thuringiensis) demonstrated at least two kinds of proteins, APNs (aminopeptidases N) and cadherin-like proteins, as possible receptors for the Cry1A class of Bt toxins. Two alternative models have been proposed, both based on initial toxin binding to a cadherin-like protein, but one involving APN and the other not. We have used two Bombyx mori strains (J65 and Kin), which are highly susceptible to Cry1Ab, to study the role of these two types of receptors on Cry1Ab toxin binding and cytotoxicity by means of the inhibitory effect of antibodies. BBMVs (brush-border membrane vesicles) of strain J65 incubated with lab…

Brush borderBacterial ToxinsBacillus thuringiensisCD13 Antigensmedicine.disease_causeBiochemistryAminopeptidaseAminopeptidasesAntibodiesHemolysin ProteinsBacterial ProteinsBacillus thuringiensismedicineAnimalsIntestinal MucosaReceptorMolecular BiologyMembranesbiologyBacillus thuringiensis ToxinsMicrovilliCadherinToxinfungiEpithelial CellsCell Biologybiology.organism_classificationBombyxMolecular biologyEndotoxinsMembrane proteinBiochemistrybiology.proteinBiological AssayAntibodyProtein BindingThe Biochemical journal
researchProduct

Decrease of mRNA levels and biosynthesis of sucrase-isomaltase but not dipeptidylpeptidase IV in forskolin or monensin-treated Caco-2 cells.

1991

International audience; Treatment for 48 h of differentiated, confluent Caco-2 cells with 2.5 10(-5) M forskolin or 10(-6) M monensin, which produces a significant decrease of the de novo biosynthesis of sucrase-isomaltase, does not change quantitatively the de novo biosynthesis of dipeptidylpeptidase IV. Western blot analysis and silver nitrate staining indicate that neither drug induces any modification in the steady state expression of these two brush border hydrolases. Northern blot analysis shows that the level of dipeptidylpeptidase IV mRNA does not change in treated as compared to control Caco-2 cells. In contrast, forskolin and monensin dramatically decrease the level of sucrase-iso…

Brush borderDipeptidyl Peptidase 4Blotting WesternAdenocarcinomaBiology03 medical and health sciencesCellular and Molecular Neurosciencechemistry.chemical_compoundWestern blot[ CHIM.ORGA ] Chemical Sciences/Organic chemistryCyclic AMPTumor Cells CulturedmedicineHumansRNA MessengerNorthern blotMonensinDipeptidyl-Peptidases and Tripeptidyl-PeptidasesMolecular Biology030304 developmental biologyPharmacology0303 health sciencesForskolinmedicine.diagnostic_test[CHIM.ORGA]Chemical Sciences/Organic chemistryColforsin030302 biochemistry & molecular biologyMonensinAntibodies MonoclonalCell BiologyMetabolismBlotting Northern[CHIM.ORGA] Chemical Sciences/Organic chemistrySucrase-Isomaltase ComplexGlucosechemistryBiochemistryCell cultureColonic NeoplasmsMolecular MedicineSucrase-isomaltase
researchProduct